CA2197139C - Medicament pour le traitement du cancer - Google Patents

Medicament pour le traitement du cancer Download PDF

Info

Publication number
CA2197139C
CA2197139C CA002197139A CA2197139A CA2197139C CA 2197139 C CA2197139 C CA 2197139C CA 002197139 A CA002197139 A CA 002197139A CA 2197139 A CA2197139 A CA 2197139A CA 2197139 C CA2197139 C CA 2197139C
Authority
CA
Canada
Prior art keywords
approximately
day
leu
cells
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002197139A
Other languages
English (en)
Other versions
CA2197139A1 (fr
Inventor
Rama Mukherjee
Manu Jaggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Immunology
Original Assignee
National Institute of Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/727,679 external-priority patent/US6156725A/en
Application filed by National Institute of Immunology filed Critical National Institute of Immunology
Publication of CA2197139A1 publication Critical patent/CA2197139A1/fr
Application granted granted Critical
Publication of CA2197139C publication Critical patent/CA2197139C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002197139A 1996-08-16 1997-02-10 Medicament pour le traitement du cancer Expired - Fee Related CA2197139C (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1822/DEL/96 1996-08-16
IN1822DE1996 1996-08-16
US08/727,679 US6156725A (en) 1996-08-16 1996-10-08 Drug for the treatment of cancer
US08/727,679 1996-10-08

Publications (2)

Publication Number Publication Date
CA2197139A1 CA2197139A1 (fr) 1998-02-17
CA2197139C true CA2197139C (fr) 2003-07-08

Family

ID=26324708

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002197139A Expired - Fee Related CA2197139C (fr) 1996-08-16 1997-02-10 Medicament pour le traitement du cancer

Country Status (3)

Country Link
JP (1) JPH1067676A (fr)
AU (1) AU707158B2 (fr)
CA (1) CA2197139C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042620C (fr) * 2011-02-02 2025-12-30 Emory University Antagonisme de la voie de signalisation piv
AU2019381809B2 (en) * 2018-11-15 2025-09-11 Emory University Compositions and uses of vasoactive intestinal peptide (VIP) antagonists

Also Published As

Publication number Publication date
AU1014997A (en) 1998-02-26
JPH1067676A (ja) 1998-03-10
CA2197139A1 (fr) 1998-02-17
AU707158B2 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
Mazel et al. Doxorubicin-peptide conjugates overcome multidrug resistance
DE69738326T2 (de) Verbindungen und verfahren zur regulierung der zellanlagerung
JP2795449B2 (ja) 治療用ペプチド
US12162937B2 (en) Methods of treating an inflammatory disorder by administering an antibody which binds to a connexin CX43 hemichannel
US20080221028A1 (en) Compositions and Methods for Treating Atherosclerosis
JP2003104998A (ja) ソマトスタチンペプチド
WO1995000542A1 (fr) Antagonistes du recepteur a la bombesine et leur utilisation
Manning et al. Selective agonists and antagonists of vasopressin
US5217953A (en) Vasoactive intestinal peptide antagonist
JPH06503090A (ja) ノナペプチドのボンベシン拮抗薬
EP0578738B1 (fr) Compositions et procedes de traitement des cancers du poumon a petites cellules ou non
Wang et al. Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway
SI9420001A (en) Polypeptide bombesin antagonists
US20250333443A1 (en) Dpep-1 binding agents and methods of use
JP2001511649A (ja) サイトカインレセプターガンマ鎖のペプチド模倣物
EP0835662B1 (fr) Médicament pour le traitement du cancer
US6156725A (en) Drug for the treatment of cancer
CN113597304A (zh) 原发性中枢神经系统淋巴瘤的组合治疗
US20110144038A1 (en) Human cd154-binding synthetic peptide and uses thereof
CN116444616A (zh) 一种lag-3蛋白的亲和肽、偶联肽、药剂和应用
CA2197139C (fr) Medicament pour le traitement du cancer
US20010053371A1 (en) Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
KR102919967B1 (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
KR20220155367A (ko) MS 치료를 위한 카파 오피오이드 수용체(kappa opioid receptor) 리간드와 조합된 사이클로타이드(cyclotide)
WO2020180144A1 (fr) Nanocage de ferritine pour la présentation multiple d'un trimère de trail et d'un peptide ciblant le cancer et son utilisation en tant qu'agent anticancéreux

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed